

# Functional Outcomes and Complications of Megaprosthetic Reconstruction in Limb-Salvage Surgery for Musculoskeletal Tumors: A Scoping Review

Anubhav Sharma<sup>1</sup>, Rishabh Guliani<sup>1</sup>, Shikhar Bindal<sup>1</sup>

## Learning Point of the Article:

Megaprosthetic reconstruction in limb salvage surgery achieves meaningful functional recovery; however, complication rates remain substantial and are influenced by anatomical site, implant characteristics, and duration of follow-up.

## Abstract

**Introduction:** Limb salvage surgery (LSS) has replaced amputation in most cases of primary malignant bone tumors, achieving comparable oncologic control while preserving limb function and quality of life. Among reconstruction techniques, megaprosthetic replacement offers immediate stability, modular flexibility, and early rehabilitation potential. However, variability in tumor site, prosthesis design, and post-operative care continues to influence functional outcomes and complication rates across regions.

**Materials and Methods:** A comprehensive scoping review of studies published between 2014 and 2025 was conducted using PubMed, Scopus, Google Scholar, and EBSCO databases. Nineteen studies involving more than 600 patients who underwent LSS with megaprosthetic reconstruction for primary or recurrent bone tumors were analysed. Extracted data included patient demographics, tumor type, prosthesis characteristics, functional outcomes (musculoskeletal tumor society [MSTS], Toronto extremity salvage score [TESS], range of motion [ROM], gait parameters, Karnofsky Performance Status [KPS], return to work), and complications such as infection, mechanical failure, and aseptic loosening.

**Results:** Functional recovery was favourable, with mean MSTS and TESS scores ranging from 66% to 89%. Distal femur reconstructions demonstrated the highest functional outcomes (>80%), while proximal femur and humerus reconstructions showed slightly reduced scores (66–73%) due to soft-tissue limitations and reduced mobility. Improvements in ROM, gait symmetry, and KPS indicated successful restoration of biomechanics and independence. Complications included deep infections (5–24%), aseptic loosening (6–15%), and mechanical failures (up to 12.5%), most commonly in expandable implants. Despite these, limb retention exceeded 88% at 5 years, and long-term implant survival remained encouraging across different centers. Socioeconomic disparities and limited access to rehabilitation were identified as key factors affecting recovery and patient satisfaction.

**Conclusion:** Megaprosthetic reconstruction remains a cornerstone of modern LSS, providing durable oncologic safety and functional restoration. Early physiotherapy, infection prevention, and careful prosthesis selection are vital for optimising outcomes. Future studies should include standardized reporting of functional and psychosocial parameters and integrate socioeconomic factors to ensure equitable, patient-centred recovery worldwide.

**Keywords:** Bone tumour, endoprosthesis, functional outcome, limb salvage surgery, megaprosthesis, reconstruction.

## Author's Photo Gallery



Dr. Anubhav Sharma



Dr. Rishabh Guliani



Dr. Shikhar Bindal

Access this article online

Website:  
www.jocr.co.in

DOI:  
<https://doi.org/10.13107/jocr.2026.v16.i05.7352>

<sup>1</sup>Department of Orthopaedics, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

### Address of Correspondence:

Dr. Rishabh Guliani,  
Department of Orthopaedics, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.  
E-mail: gulianirishab@gmail.com

Submitted: 26/02/2026; Review: 21/03/2026; Accepted: April 2026; Published: May 2026

DOI: <https://doi.org/10.13107/jocr.2026.v16.i05.7352>

© The Author(s). 2026 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

## Introduction

Limb salvage surgery (LSS) has become the preferred treatment for primary malignant bone tumors of the extremities, replacing amputation in nearly 90–95% of eligible cases while achieving comparable oncologic control [1,2]. This approach emphasizes wide tumor excision, preservation of limb function, and improved quality of life for patients. The majority of these tumors occur in load-bearing bones, with the distal femur accounting for approximately 37% of cases, followed by the proximal tibia (19%), proximal humerus, and proximal femur [3]. The principal tumor types treated with limb salvage procedures include osteosarcoma, Ewing's sarcoma, chondrosarcoma, and giant cell tumors. Advances in neoadjuvant chemotherapy, cross-sectional imaging, and reconstructive techniques have significantly improved the safety and functional success of limb-sparing surgery, leading to 5-year survival rates exceeding 60–70% in non-metastatic osteosarcoma patients [4].

Restoring limb biomechanics and function following tumor resection remains a key challenge. Various reconstructive strategies have been developed, including biological options such as allografts, autografts, arthrodesis, and rotationplasty. However, modular endoprosthetic reconstruction (megaprosthesis) has gained the widest acceptance due to its intraoperative adaptability, immediate structural stability, and facilitation of early mobilization [5,6]. These implants are particularly advantageous for metaphyseal and epiphyseal lesions where joint preservation is not feasible.

Functional outcomes following megaprosthesis reconstruction are generally favourable, with 70–85% of patients achieving good to excellent results. Functional recovery has been most commonly assessed using the musculoskeletal tumor society (MSTS) score and, in several recent studies, the Toronto extremity salvage score (TESS). Other complementary indicators – such as range of motion (ROM), gait analysis (e.g., 6 min walk test or gait deviation index [GDI]), pain reduction, Karnofsky Performance Status (KPS), and return to work capability have also been reported, providing a broader understanding of post-operative functional restoration. Despite these encouraging outcomes, residual limitations, including restricted joint motion, gait asymmetry, persistent pain, and reduced activity levels, may still impact overall quality of life.


Complications remain a major concern. Deep infections occur in approximately 10–20% of

cases, while aseptic loosening, mechanical failures, and periprosthetic fractures continue to threaten long-term prosthesis survival and may necessitate revision surgery or, in severe instances, secondary amputation [7]. These complications are influenced by tumor site, prosthesis design, and soft-tissue reconstruction Quality.

Given the complexity of reconstruction and variability in outcomes across anatomical sites, understanding functional recovery patterns, complication profiles, and prosthesis longevity is crucial for optimizing patient outcomes. Therefore, this review aims to synthesize current evidence on the functional and non-functional outcomes of megaprosthesis reconstruction following LSS, with particular attention to site-specific challenges and complication rates.

## Materials and Methods

This scoping review was conducted according to the Arksey and O'Malley scoping framework [8] and reported with reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement to enhance transparency in study identification and selection. The study selection process is illustrated in the PRISMA flow diagram (Fig. 1) [9]. A comprehensive search was performed across PubMed, Scopus, Google Scholar, and EBSCO databases for studies published between January 2014 and May 2025, guided by the population, intervention, comparison, outcome



**Figure 1:** Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 flow diagram of study selection.

Study	Risk of bias								Overall
	D1	D2	D3	D4	D5	D6	D7	D8	
Donati et al., 2016 [11].	+	-	+	-	-	+	-	-	-
Ivanov YS et al., 2023 [19].	+	-	+	-	-	+	-	-	-
Kashyap N et al., 2022 [20].	+	-	+	-	-	+	+	-	-
Ebeid WA et al., 2023 [29].	+	-	+	-	-	+	+	-	-
Jover -jorge N et al., 2024 [30].	+	-	+	-	-	+	-	-	-
Hiranya Kumar S et al., 2022 [31].	+	-	+	-	-	+	-	-	-
Kamal AF et al., 2018 [32].	+	-	+	-	-	+	-	-	-
Kumar H et al., 2023 [33].	+	-	+	-	-	+	-	-	-
Pratheep KG et al., 2020 [34].	+	-	+	-	-	+	-	-	-
Sinha SK et al., 2022 [35].	+	-	+	-	-	+	-	-	-
Bilal M et al., 2021 [36].	+	-	+	-	-	+	-	-	-
Natarajan MV et al., 2017 [37].	+	-	+	-	-	+	-	-	-
Fernandes LD et al., 2023 [38].	+	-	+	-	-	+	-	-	-
Satish MS et al., 2019 [39].	+	-	+	-	-	+	-	-	-
Pu F et al., 2023 [40].	+	-	+	-	-	+	-	-	-
Lin T et al., 2021 [41].	+	-	+	-	-	+	-	-	-
Pesenti S et al., 2018 [42].	+	-	+	-	-	+	-	-	-
Ng YH et al., 2024 [43].	+	-	+	-	-	+	-	-	-
Shah MR et al., 2020 [44].	+	-	+	-	-	+	-	-	-

D1: Selection: Representativeness of the exposed cohort  
 D2: Selection: Selection of the non-exposed cohort  
 D3: Selection: Ascertainment of exposure  
 D4: Selection: Demonstration that outcome of interest was not present at start of study  
 D5: Comparability: Comparability of cohorts on the basis of the design or analysis  
 D6: Outcome: Assessment of outcome  
 D7: Outcome: Was follow-up long enough for outcomes to occur  
 D8: Outcome: Adequacy of follow up of cohorts

Judgement  
 High (Red)  
 Moderate (Yellow)  
 Low (Green)

Figure 2: Risk of bias assessment of included non-randomized studies using the Newcastle Ottawa scale.

framework (Table 1). A structured combination of MeSH terms and keywords related to bone tumors, LSS, endoprosthetic or megaprosthesis reconstruction, and functional or complication outcomes was applied, with detailed search logic outlined in (Table 2). The initial search yielded 324 records, and after duplicate removal and screening, 47 full-text articles were assessed, of which 19 met the inclusion criteria. Eligible studies were English language publications (2014–2025), available in full text, focusing on LSS using modular or custom megaprosthesis reconstruction for primary or recurrent bone tumours, and reporting at least one functional outcome (e.g., MSTs, TESS, ROM, pain, or quality of life) and at least one complication outcome (infection, mechanical failure, aseptic loosening, or revision surgery). Excluded were studies with fewer than five patients, conference abstracts, reviews, non-English papers, non-extractable data, or follow-up shorter than 6 months.

Methodological quality and risk of bias of the included non-randomized observational studies were assessed using the Newcastle Ottawa scale (NOS) for cohort studies. The critical appraisal skills programme checklist [10] was used as a supportive framework to aid critical appraisal and interpretation of study findings. The assessment evaluated

three key domains: Selection of study cohorts, comparability of cohorts based on study design or analysis, and adequacy of outcome assessment and follow-up. Risk of bias judgments for individual NOS domains were summarized and visualised using the risk of bias tool, employing a generic risk of bias framework. After the bias assessment, data were extracted using a structured template (Table 3) documenting study design, sample size, demographics, tumor type and site, prosthesis details, surgical margins, follow-up duration, functional outcomes, and complication profiles. Due to heterogeneity in study design, prosthesis models, and outcome reporting, results were synthesised through a qualitative narrative approach rather than meta-analysis. The review further analysed patterns in functional recovery, complication rates, prosthesis survivorship, and regional practice trends, while identifying gaps in evidence concerning long-term implant performance, rehabilitation protocols, and design innovation to inform future research directions.

Results

Study scope and patient demographics

This review included 19 studies published between 2014 and 2025, encompassing a total of 610 patients who underwent LSS with megaprosthesis reconstruction for primary or recurrent bone tumors. Patient ages ranged from 13 to 47 years, with several studies focusing on pediatric and adolescent groups receiving expandable prostheses. Geographically, India contributed eight studies, followed by China (three), Egypt (two), France (two), and one each from Spain, Bulgaria, Denmark, and Pakistan. Study designs comprised prospective cohorts, retrospective series, cross-




Figure 3: Mean musculoskeletal tumour society scores by anatomical site.



**Table 1: The PICO framework guided search strategy and selection criteria**

Component	Description
Population	Patients undergoing limb salvage surgery for primary or recurrent bone tumours
Intervention	Metaprosthesis or megaprosthesis reconstruction using modular endoprosthesis
Comparison	Historical cohorts or alternative limb salvage techniques
Outcomes	Functional outcomes (MSTS, TESS, ROM, gait), psychological recovery, pain relief, return to work and complications
<b>PICO: Population, intervention, comparison, outcome, MSTS: Musculoskeletal tumor society, TESS: Toronto extremity salvage score, ROM: Range of motion</b>	

sectional, and case-control studies, with follow-up durations ranging from 6 months to more than 8 years.

### Risk of bias assessment

Overall, the included studies demonstrated predominantly moderate risk of bias across NOS domains. Most studies showed low risk in selection representativeness and outcome assessment, reflecting well-defined cohorts and the use validated functional outcome measures. However, comparability between cohorts was frequently limited due to a retrospective study design and a lack of adjustment for confounding variables. In several studies, the absence of a clearly defined non-exposed comparator group contributed to higher risk ratings in selection-related domains. Follow-up duration and adequacy were generally moderate, with variability in reporting of loss to follow-up. A summary of the domain-specific risk of bias assessment is presented in Fig. 2.

### Surgical techniques and prosthesis types

Across the included literature, both modular and custom megaprotheses were used, with common systems including MUTARS, RESTOR, GMRS, and silver-coated or cemented variants. Modular implants predominated in India, China, and Egypt because of their cost-effectiveness, intraoperative adaptability, and ease of revision, whereas custom implants were favoured in European centers for precise anatomical reconstruction in complex resections. Silver-coated prostheses demonstrated lower infection rates (7.9% vs. 16.7%) and improved revision-free survival [11,12], while cemented fixation allowed earlier weight bearing and faster mobilization. Modular systems also facilitated simpler revision procedures in cases of loosening or mechanical failure [13,14,15].

### Functional outcomes

Functional recovery was favourable, influenced by rehabilitation intensity, early mobilisation, prosthesis design, and anatomical site [16]. The MSTS score was the predominant outcome tool, while three studies also used the TESS. Additional parameters such as ROM, gait and biomechanical analysis (6-min Walk Test, Timed Up and Go, GDI), pain scores (Visual Analog Scale), KPS, and return to work or activities of daily living measures were variably reported.

Across all cohorts, MSTS/TESS scores ranged from 66.6% to 89.7%, indicating good to excellent limb function. The distal femur remained the most frequently reconstructed site and consistently yielded mean MSTS scores exceeding 80%, attributed to better biomechanics, soft-tissue coverage, and structured physiotherapy [17]. Proximal femur and proximal humerus reconstructions showed lower functional scores (66–73%), reflecting abductor weakness and limited joint mobility [18,19] (Fig. 3). ROM data were reported in eight studies, with mean knee flexion ranging between 80° and 110° post-rehabilitation, extension lag of 5–20° in proximal tibial cases, and shoulder abduction between 70–90° after proximal humeral reconstruction. Biomechanical assessments were presented in three European studies, which demonstrated near-normal gait kinematics with GDI values of 86–89 compared to 94 in healthy controls and mildly prolonged 6MWT and TUG times. In Pu et al. (2023), KPS improved significantly from 50 preoperatively to 70–90 postoperatively, indicating restored independence. Early physiotherapy and weight bearing within 6–8 weeks were consistently associated with superior function, faster gait recovery, and higher satisfaction [20].

### Non-functional outcomes

Non-functional results, including oncologic control, prosthesis

**Table 2: Keywords**

Search domain	Keywords and synonyms
Bone tumours	Osteosarcoma, Ewing sarcoma, Chondrosarcoma, giant cell tumour, Bone neoplasm
Limb salvage surgery	Limb preserving surgery, endoprosthetic resection, megaprosthesis, modular implants
Functional outcomes	MSTS, TESS, mobility, gait, range of motion (ROM), rehabilitation
Quality of life	Psychological acceptance, pain relief, return of work, and daily activity resumption
<b>MSTS: Musculoskeletal tumor society, TESS: Toronto extremity salvage score</b>	



**Table 3: Data extraction table (11, 19, 20, 26, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)**

Author and year	Study design and location	Sample size	Demographics	Tumour type	Site	Indication	Type of prosthesis	Surgical margin	Follow-up duration	Functional outcome	Non-functional outcome	Complication	Limb survival	Prosthesis survival	Conclusion
Datta et al., 2024 [11]	Retrospective study, India	68 patients	Mean age 61.8 years, 31 M, 37 F	Primary bone tumours (23) OS, ES, CK, malignant fibrous histiocytoma, GCT, metastatic bone tumours (45)	Proximal femur	Oncologic limb salvage surgery	Silver coated hip hemiarthroplasty (55.9%) versus uncemented megaprosthesis (44.1%)	Wide resection	Mean 65 months	MSTS score comparable between silver coated and uncemented prosthesis; mobility, pain reduction and overall recovery showed no significant difference.	No sign of local or general silver toxicity reported.	Infection (11%), silver coated, 16.7% (n=26); prosthesis degradation observed after 6-18 months.	Majority retained limb function, silver coated implants showed reduced early infection rate.		Silver coated prosthesis lower early infection rate but cemented options diminish over time due to wear; recommended for primary implantation in limb salvage surgery.
Ivanov and Ivanov 2023 [19]	Retrospective analysis, Bulgaria	14 patients	10 males, 4 females	ES (7), OS (4), GCT (1), CS (1), CB (1)	Humerus, tibia, femur most common: distal femur	Primary malignant bone tumour	Modular tumour prosthesis (metals, metal-spinal)	Wide resection (AKCC system)	Mean 35.3 months (8-96)	MSTS score 70%	Improved quality of life, early rehabilitation, weight bearing possible.	Local recurrence (1), distal humerus (4), proximal humerus (3), periprosthetic nerve injury (1), mechanical failure in uncemented prosthesis (1)	Majority retained limb function, 2 patient deceased due to disease complication.	Asaptic loosening, mechanical failure.	Modular tumour endoprosthesis provide excellent functionality and improved quality to patients.
Kalyoglu et al., 2022 [20]	Retrospective cohort study, India	28 patients	Mean age: 30.0 (10-50 years), 18 male, 10 female	GCT (53.0%), OS (23%), chondrosarcoma (13%), primitive femur (13.8%)	Distal femur (57.1%), proximal femur (32.2%), proximal tibia (7.1%), proximal tibia (3.0%)	Limb salvage surgery for benign/malignant bone tumours.	Modular segmental-replacement system prosthesis.	Wide resection confirmed via MRI and biopsy.	Median: 80 months	Mean MSTS score: 25.0 (4-3), proximal femur: 23.0 (4-8), distal femur: 26.0 (4-4), proximal tibia: 16.5 (4-4)		Log length discrepancy (25%) proximal femur (17.1%), distal femur (16.5%), proximal tibia (16.5%), proximal tibia (16.5%)	83.7% relative free survival at median follow-up of 80 months.	83.7% at 80 months.	Modular tumour endoprosthesis inferior to cemented endoprosthesis but function, cost selection is key.
Elhad et al., 2023 [29]	Retrospective study, Egypt	55 patients	30 M, 25 F, mean age: 19 years	Proximal tibial osteosarcoma	Proximal tibia	Limb salvage surgery	Modular endoprosthesis.	Wide resection	Mean: 71.69 months	MSTS score: Mean 26.5 (2-22), mean range: 15.00-31.38	Psychological benefits of limb salvage surgery; improved extension lag.	Sub-tensor failure (7.3), upper-limb amputation (14.5), structural failure (21.5%), aseptic loosening (23.6%), infection (23.6%), local tumor progression (25.7%), long-term outcomes (18.2%)	5-year: 88.2%; 10-year: 88.2%	5-year: 88.2%; 10-year: 88.2%	Modular endoprosthesis is a reliable limb salvage option; most complication are amputations.
Jover-Jorge et al., 2024 [36]	Case-control study, Spain	31 patients, 48 controls (dualities)	Mean age: 39.3 years (patients), 42.4 years (controls), 17 M, 14 F	OS, CK, GCT, plasmacytoma, undifferentiated sarcoma	Distal femur	Musculoskeletal tumours	Distal femur megaprosthesis (cemented, uncemented, cementing/locking)	N/A	49.3 months	MSTS score: 22 (range 4-29)	IC-50 physical component significantly lower than controls, mental component comparable to controls.	Knee extension weakness, reduced knee flexion range, limb length discrepancy, aseptic loosening, recurrence	Majority retained limb function, 5 patients deceased due to disease complication.	Asaptic loosening, recurrent surgery requirements.	Knee extension strength and ROM strongly influence functional recovery; rehabilitation should prioritize strength and mobility.
Kumar et al., 2022 [11]	Prospective study, India	64 patients	30 M, 34 F, age range: 14-64 years	GCT (primary 29, recurrent 12, OS (range 6-48), chondrosarcoma (9)	Distal femur (34), proximal tibia (30)	Musculoskeletal tumour	Modular tumour prosthesis (metal system)	Wide excision with acceptable margin (smoking, staging system)	5-year follow-up	MSTS score: Distal femur (76.4%), proximal tibia (71.1%), overall (73.0%)	Majority returned to work, functional limb required.	Surgical site infection (1), aseptic loosening (4 patients), recurrence requiring amputation (1 patient)	Majority retained limb function, 1 patient required amputation due to recurrence.	Asaptic loosening	Modular tumour endoprosthesis provide good functional outcome; avoid knee long-term patient survival remain consistent.
Kumar et al., 2018 [32]	Prospective case series, India	32 patients	17 M, 15 F, age range: 13-64 years	OS (14), metastatic bone disease (23), pet (15), chondro sarcoma (10)	Distal femur (15), proximal tibia (13), proximal femur (4)	Oncologic limb salvage	Megaprosthesis reconstruction	Wide excision with acceptable margin (smoking, staging system)	24 months	MSTS improvement from mean 5.3 (pre-op) to 25.2 (post-operative)	Quality of life improved, pain reduced.	Infection, knee dislocation, nerve injury, recurrence, periprosthetic fracture	Majority retained limb function, 4 patient deceased	Sub-tensor reconstruction and infection.	Megaprosthesis is effective but has complication; geographic barriers impact follow up care.
Kumar et al., 2021 [11]	Prospective study, India	32 patients	14 M, 28 F, mean age: 31 years	GCT (17, 53.1%), OS (9, 28.1%), secondary tumours (5, 15.6%), fibrous dysplasia (1, 3.2%)	Proximal femur	Oncologic limb salvage surgery	Modular endoprosthesis	Wide excision with acceptable margin (smoking, staging system)	5 years (2012-2019)	MSTS score: 72.84% overall, evaluating gait, walking, shoulder and hip, pain reduction.	Improved quality of life, mobility recovery, pain reduction.	Infection (12.5%), dislocation (9.25%), aseptic loosening (9.25%), no amputations	All patients retained limb function, no major loss.	Survivorship affected by soft tissue atrophy, infection, mechanical failure.	Modular endoprosthesis is an effective limb salvage option; improving function and quality of life.
Pathak et al., 2020 [13]	Prospective study and retrospective study, India	20 patients	14 M, 6 F, age range: 11-50 years	OS (9), GCT (7), chondrosarcoma (1), plasmacytoma (1)	Distal femur (12), proximal tibia (5), proximal femur (2)	Oncologic limb salvage	Custom-made endoprosthesis	Wide excision	Min. 6 months, maximum years (mean 2.6 years)	MSTS score: Mean 66.5% (6 patients excellent) (79%), 1 good (100.0%) 2 fair (50.0%)	Functional acceptance lower due to prosthesis weight	Nerve palsy (1), wound dehiscence (1), loosening (1), prosthesis breakage (1)	19 patients retained limb function, 1 required amputation	Affected by infection and mechanical failure.	Custom made endoprosthesis is effective for limb salvage, but outcome can be influenced by surgical expertise and rehabilitation.
Saha et al., 2021 [14]	Prospective study, India	14 patients	10 M, 4 F, age range: 15-48 years, mean 35.8 years	OS, CK, GCT, locally metastatic tumours	Distal femur, proximal tibia, proximal femur, proximal tibia	Oncologic limb salvage	Custom made metallic megaprosthesis.	Wide resection (en bloc staging)	Minimum 1.5 years	MSTS score: 85.5 (3-94), knee society score: 90.5 (excellent shoulder score: 41.67)	Improved anatomical acceptance, pain reduction, strength maintenance.	Hip dislocation (1), superficial infection (1), no implant loosening, recurrence or amputation.	All patients retained limb function.	No failure, stable long-term results.	Endoprosthesis effectively preserve limb function with high emotional acceptance and minimal complication.
Bhal et al., 2021 [35]	Retrospective study, Pakistan	43 patients	Mean age 26.5 years, 30 M, 13 F	OS (27), CS (5), ES (3), plasmacytoma (1), diffuse large B-cell lymphoma (1)	Distal femur (19), proximal tibia (7), proximal femur (6), proximal humerus (1)	Oncologic limb salvage	Modular mega prosthesis	Wide resection (negative margins)	Mean 23.3 months	MSTS score improved from 11.70 (pre-op) to 39.90 (post-operative); distal femur had highest ratio (41.45)	Better quality of life, mobility recovery, correlation between site infection and pain scores.	Prosthesis pain (4.5%), infection (9.3%), mortality (6.7%)	Retained limb function in majority, 1 amputation due to infection.	Failure due to aseptic loosening, periprosthetic fracture, implant breakage.	Limb salvage surgery with mega prosthesis offers satisfactory functional outcomes but requires further study.
Natarajan et al., 2021 [36]	Retrospective study, India	6 patients (from a large cohort of 119 osteosarcoma cases)	Mean age 24.2, 5 M, 1 F	Metastatic osteosarcoma (conventional subtype)	Distal femur (3), proximal tibia (1), distal humerus (1), distal radius (1)	Oncologic limb salvage	Custom-made endoprosthesis	Wide resection	Mean 2.43 years	MSTS score: Primary tumour 22.9, metastatic tumour 19.5 (lower at humerus and tibia)	Good functional recovery; poorer outcomes for proximal humerus and distal tibia cases.	Pain (2 patients), central metatarsal (2)	Majority retained limb function except 2 patients which got metastatic disease.	Stable results with follow-up surgical indicated early detection.	Metastatic osteosarcoma should be recognized in long-term survivors; limb salvage with custom prosthesis viable good results.
Fernandes et al., 2023 [17]	Cross-sectional study, Denmark	20 patients, 20 controls	Mean age: 43 years (20-71)	Os, os, pet	Proximal femur (9), distal femur (7), proximal tibia (4)	Work ability and physical activity post-surgery bone tumours	Work ability and physical activity post-surgery bone tumours	Wide resection	Mean 7 years	MSTS score: 70% (patients), 97% (control)	Lower work ability, difficult performing self selected activities	Reduced work ability in relation to physical demands.	Patients maintained limb function but reported work-related impact on long-term stability.	Stable result with follow-up impact on long-term work-related stability.	Patients had lower work ability and active activity limitation despite similar physical activity work-related stability; work ability assessment.
Saithi et al., 2019 [34]	Cross-sectional study, India	32 patients (17 revision too, 17 amputees)	Age 16-65 years, mean age: 29 years	Os (75%), soft-tissue sarcoma (25%)	Distal femur (9/73), proximal tibia (4/63)	Revision limb salvage surgery versus above-knee amputation.	Custom mega prosthesis	Wide resection confirmed	6-18 months.	MSTS scores revision (80.44%) vs amputees (79.70%); no had better emotional acceptance, emotional well-being, function	Fear of recurrence higher in both patients, amputees had better pain control.	Loosening, fracture, infection, amputation had better psychological acceptance.	LSB patients had improved body image but fear of recurrence.	Camp challenges in long-term use	Limb salvage surgery had better functional outcomes and body image, but increased fear of recurrence compared to amputation.
Pei et al., 2023 [39]	Retrospective study, western China	18 patients	11 M, 7 F, age range: 46-79 years	Metastases from lung cancer (7), kidney cancer (4), breast cancer (2), thyroid cancer (2), cervical cancer (1), osteosarcoma (1), stomach cancer (1)	Femoral shaft	Limb salvage surgery for femoral shaft metastases	Customized modular prosthesis (60 x14 x alloy)	In situ resection of diseased bone.	Mean: 25.28 months (range 12-42 months)	MSTS scores improved significantly (pre-op: 22.1/11, 76; post-operative: 28.7/12.1), limb function also improved (pre-op: 3.0/1.66, post-operative: 28.19/1.72)	Pain reduction (VAS scores significantly decreased from 8.54 to 4.02 to 2.45 (P<0.02); improved quality of life (Kamada) performance score increased from 61.81 to 58.38 to 74.87 (P=1.72)	Pain reduction (VAS scores significantly decreased from 8.54 to 4.02 to 2.45 (P<0.02); improved quality of life (Kamada) performance score increased from 61.81 to 58.38 to 74.87 (P=1.72)	Two cases of aseptic loosening; no local recurrence; no limb length discrepancy.	Stable results, two cases of loosening, but no reoperation (77.78%)	In situ resection and modular prosthesis implantation effectively reduce pain and improve function; limb salvage is a viable option for femoral shaft metastases.
Lin et al., 2021 [40]	Retrospective study, China	53 patients	Mean age 28 years, 37 M, 16 F	Osteosarcoma	Distal femur (30/5), proximal tibia (4/3), proximal femur (1/3)	Limb salvage surgery with segmental tumour endoprosthesis replacement.	Segmental tumour endoprosthesis replacement.	Wide resection	Mean age 48 months	Mean MSTS score of 20.	Limb salvage preserved function, delayed recovery due to infection risk.	Periprosthetic infection (1.0%), aseptic loosening (3), recurrence (2), metastatic-related death (2)	Majority retained limb function, 9 patient required amputation.	Two major revision introduced.	Periprosthetic infection risk increases with prolonged surgery and high blood loss; 2 major revision remains effective.
Poemi et al., 2018 [41]	Retrospective study, internationally university, France	18 patients (6 megaprosthesis, 9 allografts + 10 controls)	Mean age 25.2 years	Distal femur osteosarcoma and ewing sarcoma	Distal femur	Limb salvage surgery	Megaprosthesis (fixed hinge limb replacement) versus allograft with emphasis on spring (circularized tibial)	Wide resection (2 cm)	Mean: 10.3 years	MSTS score: Megaprosthesis (79.4%), allograft (81.1%), no significant pain score difference between groups pre-Megaprosthesis (36.4), allograft (48.4) controls (84)	No significant difference in global function; megaprosthesis may have concern for prosthesis wear due to specificity weakness.	Distraction lock fixation in megaprosthesis patients during stance gait; quadriceps weakness affected gait.	Majority retained limb function with adjusted gait mechanics.	Megaprosthesis patients gait unique gait adaptations that may influence long-term wear.	No major difference between megaprosthesis and allograft in gait function; gait modifications may be caused by quadriceps weakness, not prosthesis limitations.
Ng et al., 2024 [42]	Retrospective cross-sectional study, Malaysia	65 patients	Mean age 35.93 years, 51 M, 25 F	Os (46.4%), pet (19.6%), ES (7.1%), whole femur (3.9%), fibrous (12.3%), aggressive pet (1%), spindle cell sarcoma (2.3%), synovial sarcoma (2.3%)	Proximal humerus (10%), proximal femur (13%), distal femur (47%), proximal tibia (10%)	Limb salvage surgery with cemented endoprosthesis.	Cemented endoprosthesis	Clear margin (82.1%), margin involved (17.9%)	Mean: 3.2 years (range 2-9 years), 70% followed up more than 3 years.	MSTS score reported, with better results for clear margin cases.	Psychological acceptance high in successful limb salvage cases.	Structural failure (16.1%), infection (14.2%), tumor recurrence (25%), hip dislocation (4.6%)	Comparable with global data; failure rate excluding central patient selection is crucial for optimizing outcomes.	30.4%	Endoprosthesis reconstruction results align with global literature; central patient selection is crucial for optimizing outcomes.
Bhal et al., 2021 [43]	Retrospective study, Pakistan	40 patients	28 M, 12 F, age range: 6-67 years	Osteosarcoma (57%), chondrosarcoma (12%), primitive femur (13%), secondary bone tumours (10%), aggressive pet (1%), spindle cell sarcoma (2.3%), synovial sarcoma (2.3%)	Proximal humerus (10%), proximal femur (13%), distal femur (47%), proximal tibia (10%)	Limb salvage surgery with megaprosthesis.	Cemented megaprosthesis replacement	Wide marginal excision (1 cm)	Mean: 3.2 years (range 2-9 years), 70% followed up more than 3 years.	MSTS score: Knee (20), proximal femur (22), proximal humerus (13)	Better psychosocial acceptance; positive mood improved functional outcome.	Superficial infection (2.5%), delly infection (2.5%), fat embolism (2.5%), tumor recurrence (25%), hip dislocation (4.6%)	92.5% tumor-free at final follow-up; one patient died post-surgery.	No implant-related complications or revisions.	Limb salvage surgery with megaprosthesis provides good functional and functional outcomes in selected cases; requires a specialized team-based approach.

ES: Ewing sarcoma, OS: Osteosarcoma, GCT: Giant cell tumor, CS: Chondrosarcoma, CB: Chondroblastoma, M: Male, F: Female, VAS: Visual Analog Scale

longevity, and psychosocial recovery, were encouraging. Local recurrence ranged from 6.45% to 9.3% [13,14], while metastatic spread occurred in 7–18.2% of patients [17,18]. Five-year limb retention rates exceeded 88% in nearly all cohorts, with several reporting stable 10-year survivorship [11,12]. For example, Ebeid et al. (2023) documented 82.1% wide surgical margins and only 7% secondary amputations due to recurrence or severe complications. Distal femur reconstructions achieved the best local control [14], whereas proximal humerus and pelvic reconstructions carried slightly higher recurrence risks [19]. Psychosocial and return to work outcomes were addressed in five studies. Fernandes et al. (2023) reported 70% return to employment with a mild reduction in work capacity compared to controls, while Satish et al. (2019) and Jover-Jorge et al. (2024) observed better emotional well-being, self-image, and social reintegration among limb salvage patients compared to amputees. Ebeid et al. (2023) and Ivanov et al. (2023) similarly reported high patient satisfaction and improved quality of life following structured rehabilitation [21].

### Complications and survivorship

Complications influenced long-term outcomes, with deep infection being the most common (5.1–23.6%), particularly in Egyptian and Chinese cohorts, despite the use of silver coatings [11,13]. Aseptic loosening occurred in 6.25–14.5% of patients, primarily in Indian and Pakistani studies [14,15]. Mechanical failures – including prosthetic breakage, hinge malfunction, periprosthetic fracture, and expansion mechanism defects – were observed in 6.5–12.5% of cases, with higher incidence among skeletally immature patients undergoing expandable reconstructions due to repeated lengthening and growth stresses [22]. A bar chart demonstrating pooled mean incidence of major complications following megaprosthesis reconstruction, including infection, aseptic loosening, mechanical failure, local recurrence, and metastasis (Fig. 4). Despite these complications, implant survival remained robust, with 5-year limb retention consistently above 88% and multiple studies reporting durable functionality beyond 10 years [11,12].



## Discussion

Recovery after LSS extends far beyond restoring bone and muscle – it represents the restoration of independence, identity, and quality of life. Across the 19 core studies ( $n > 600$ ), patients frequently described regaining the ability to walk independently, return to work, and reclaim personal autonomy as defining milestones of recovery. Collectively, these outcomes reaffirm that megaprosthesis reconstruction is not merely a technical triumph but a means of restoring function and dignity. Long-term survivorship data have been equally encouraging, with several reports demonstrating that proximal femoral endoprostheses achieve more than 85% survival at 10 years, underscoring their durability in experienced oncologic centers [23].

Interpretation of these results, however, must be cautious given the predominance of retrospective designs, limited randomization, and heterogeneity in implant types and follow-up durations across studies. Functional outcomes, most commonly assessed through the MSTS and TESS, consistently demonstrated good to excellent recovery, with mean values ranging between 66% and 89%. These scores reflect an overall improvement in limb function, pain reduction, emotional acceptance, and independence in daily activities – highlighting that megaprosthesis reconstruction achieves both mechanical and functional recovery. Parallel gains in joint mobility and gait performance confirmed smoother biomechanical adaptation and efficient ambulation following structured rehabilitation. Improvements observed in performance indices such as the GDI and Timed Up and Go tests suggest that patients achieved near-normal walking symmetry and endurance. Similarly, higher KPS and increased return to work rates underscored the restoration of physical capacity, self-care ability, and social reintegration. Together, these multidimensional improvements confirm that LSS restores not only the integrity of the limb but also the patient's overall quality of life and independence.

Hardes et al. demonstrated that silver-coated prostheses reduce infection risk by nearly half, offering a valuable preventive strategy against one of the most devastating complications [24]. Nevertheless, mechanical failures – including hinge fractures, component fatigue, aseptic loosening, and expansion mechanism defects remain significant challenges, particularly among children and adolescents treated with expandable implants, where repeated lengthening increases mechanical stress and revision rates [25]. Early initiation of rehabilitation and progressive weight bearing after reconstruction have been repeatedly shown to enhance functional recovery, accelerate ambulation independence, and improve MSTS and TESS scores among limb salvage patients [26].

Beyond surgical technique, social and economic contexts profoundly influence long-term outcomes. Gronchi et al. (2021) emphasised that optimal sarcoma management should be centralised in multidisciplinary reference centers where surgeons, oncologists, physiotherapists, and psychologists collaborate to optimise oncologic control, functional recovery, and emotional adaptation [27]. Duijts et al. (2014) further noted that even after successful physical recovery, many cancer survivors face ongoing psychosocial barriers, including anxiety and challenges returning to work or social activities [28]. In resource-limited settings, modular systems are often preferred due to their affordability and versatility; however, restricted access to structured rehabilitation and socioeconomic constraints can impede functional recovery and quality of life outcomes. Future studies should incorporate socioeconomic indicators such as income, education, and rehabilitation access to present a more comprehensive picture of recovery trajectories.

From an oncologic standpoint, achieving wide surgical margins remains the cornerstone of durable limb preservation. Ebeid et al. reported that 82% of patients with histologically clear margins retained their limbs at 5 years, reaffirming the delicate balance between oncologic safety and functional preservation [29]. By systematically searching four major databases, we were able to map both outcomes and complications rates over 600 patients worldwide. This provides a broad and realistic picture of how megaprosthesis reconstruction perform across different anatomical sites and healthcare settings. Because the included studies varied significantly in their study design, prosthetic models and follow-up durations, a statistical meta analysis was unable to be conducted. Furthermore, our review is limited by available literature as most of the underlying studies are retrospective and single-center series. Progress in this field now depends on methodological refinement. Moving forward, the establishment of multi-center registries that incorporate standardised definitions, validated patient-reported outcome measures (PROM's), and socioeconomic variable is essential. This will enable better comparison and help guide global best practices.

## Conclusion

This scoping review demonstrates that megaprosthesis LSS provides durable oncologic control and reliable functional restoration for patients with primary or recurrent bone tumours. Functional outcomes were consistently favourable, particularly in distal femur reconstructions, with strong long-term implant survival across studies. Although complications such as infection, aseptic loosening, and mechanical failure persist, modern modular and silver-coated prosthetic designs

combined with structured rehabilitation have markedly improved long-term results. Future progress will depend on multi-center collaboration, standardized outcome measures, and the integration of socioeconomic and rehabilitation factors into future research, ensuring that advances in implant technology translate into equitable, patient-centered improvements in mobility and quality of life.

### Clinical Message

Megaprosthetic reconstruction remains a technical cornerstone of modern limb salvage surgery (LSS). While it offers immediate stability and early mobilization, the balance between functional gain and long term complications requires careful patient selection and site specific expectations.

**Declaration of patient consent:** The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given the consent for his/ her images and other clinical information to be reported in the journal. The patient understands that his/ her names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Conflict of interest:** Nil **Source of support:** None

### References

1. Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. *J Bone Joint Surg Am* 1986;68:1331-7.
2. Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. *J Bone Joint Surg Am* 1994;76:649-56.
3. Dharanikota A, Arjunan R, Dasappa A. Factors affecting prognosis and survival in extremity osteosarcoma. *Indian J Surg Oncol* 2021;12:199-206.
4. Bacci G, Mercuri M, Longhi A. Neoadjuvant chemotherapy for osteosarcoma of the extremity. *J Clin Oncol* 2005;23:8845-52.
5. Grimer RJ, Aydiner B, Wafa H, Carter SR, Jeys L, Abudu A, et al. Very long-term outcomes after limb salvage surgery with endoprosthesis for bone tumors. *Clin Orthop Relat Res* 2016;474:706-15.
6. Jeys LM, Kulkarni A, Grimer RJ, Carter SR, Tillman RM, Abudu A. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. *J Bone Joint Surg Am* 2008;90:1265-71.
7. Henderson ER, Groundland JS, Pala E. Failure mode classification for tumor endoprostheses. *Clin Orthop Relat Res* 2011;469:1704-3.
8. Arksey H, O'Malley L. Scoping studies: Towards a methodological framework. *Int J Soc Res Methodol* 2005;8:19-32.
9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
10. Critical Appraisal Skills Programme (CASP). CASP Checklists. Available from: <https://casp-uk.net/casp-tools-checklists> [Last accessed on 2025 May].
11. Donati F, Di Giacomo G, D'Adamio S, Ziranu A, Careri S, Rosa MA, et al. Silver-coated hip megaprosthesis in oncological limb salvage surgery. *Biomed Res Int* 2016;2016:9079041.
12. Zajonz D, Birke U, Ghanem M, Prietzel T, Josten C, Roth A, et al. Silver-coated modular megaendoprostheses in salvage revision arthroplasty after periimplant infection with extensive bone loss - a pilot study of 34 patients. *BMC Musculoskelet Disord* 2017;18:383.
13. Ahlmann ER, Menendez LR, Kermani C, Gotha H. Survivorship and clinical outcome of modular endoprosthetic reconstruction for neoplastic disease of the lower limb. *J Bone Joint Surg Br* 2006;88:790-5.
14. Shehadeh A, Noveau J, Malawer M, Henshaw R. Early complications and outcomes of cemented endoprosthetic reconstruction after resection of primary bone tumors. *Ann Surg Oncol* 2010;17:524-35.
15. Pala E, Trovarelli G, Calabrò T, Angelini A, Abati CN, Ruggieri P. Survival of modern knee tumor megaprosthesis: Failures, functional results, and a comparative statistical analysis. *Clin Orthop Relat Res* 2015;473:891-9.
16. Batta V, Coathup MJ, Parratt MT. Effect of rehabilitation and patient factors on functional outcome after endoprosthetic replacement for bone tumors of the lower limb. *J Bone Joint Surg Br* 2010;92:1152-8.
17. Puri A, Gulia A, Agarwal MG, Reddy K, Patil V. Functional outcome of limb salvage surgery with megaprosthesis for primary bone tumours of the lower limb. *Indian J Orthop* 2012;46:470-6.
18. De Gori M, D'Arienzo A, Andreani L, Beltrami G, Campanacci DA, De Biase P, et al. Complications and survival of megaprosthesis after resection of bone metastases. *J Biol*



Regul Homeost Agents 2017;31:43-50.

19. Ivanov YS, Tsenkov T. Functional results after reconstruction with modular tumor endoprostheses in patients with malignant bone tumors. *Folia Med (Plovdiv)* 2023;65:80-6.
20. Kashyap N, Runu R, Ahmed W, Kumar I, Subash A. A retrospective cohort analysis of limb salvage surgery using mega prosthesis in bone tumours at a tertiary care centre in Eastern India. *Cureus* 2022;14:e28959.
21. Aksnes LH, Bauer HC, Jebsen NL, Folleras G, Allert C, Haugen GS, et al. Limb-sparing surgery preserves more function and quality of life than amputation: A long-term follow-up of extremity sarcoma patients. *Acta Orthop* 2008;79:106-12.
22. Öztürk R. Expandable endoprostheses in skeletally immature patients: Where we are. *World J Orthop* 2024;15:312-7.
23. Wedin R, Bauer HC. Surgical treatment of skeletal metastatic lesions of the proximal femur: Endoprosthesis or reconstruction nail? *J Bone Joint Surg Br* 2005;87:1653-7.
24. Harges J, Von Eiff C, Streitbuerger A, Balke M, Budny T, Henrichs MP, et al. Reduction of periprosthetic infection with silver-coated megaprotheses in patients with bone sarcoma. *J Surg Oncol* 2010;101:389-95.
25. Dotan A, Dadia S, Bickels J, Nirkin A, Flusser G, Issakov J, et al. Expandable endoprosthesis for limb-sparing surgery in children: Long-term results. *J Child Orthop* 2010;4:391-400.
26. Shehadeh A, El Dahleh M, Salem A, Sarhan Y, Sultan I, Henshaw RM, et al. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients' outcome. *Hematol Oncol Stem Cell Ther* 2013;6:105-11.
27. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(☆). *Ann Oncol* 2021;32:1348-65.
28. Duijts SF, Van Egmond MP, Spelten E, Van Muijen P, Anema JR, Van Der Beek AJ. Physical and psychosocial problems in cancer survivors beyond return to work: A systematic review. *Psychooncology* 2014;23:481-92.
29. Ebeid WA, Hassan MH. Functional outcome following proximal tibial osteosarcoma resection and reconstruction by modular endoprosthesis. *Ann Surg Oncol* 2023;30:1914-25.
30. Jover-Jorge N, González-Rojo P, Amaya-Valero JV, Baixuali-García F, Calva-Ceinós C, Angulo-Sánchez MÁ, et al. Evaluating functional outcomes and quality of life in musculoskeletal tumor patients with distal femoral megaprotheses: A case-control study. *World J Surg Oncol* 2024;22:341.
31. Kumar H, Mitemari KN, Nimmagadda VC, Abraham AT, Nadagouda S, Choudry D. The functional outcome of limb salvage of proximal femur tumors with modular endoprosthesis: A prospective study. *Cureus* 2023;15:e50375.
32. Kamal AF, Pitarini A, Prabowo Y. Megaprosthesis limb salvage surgery: Outcome and challenges in treating advanced bone tumour cases in vast archipelago in Indonesia. A case series. *Int J Surg Open* 2018;11:30-6.
33. Pratheep KG, Karthikeyan S, Pandiaselvan A. Analysis of the functional outcome of limb salvage procedure using custom-made endoprosthesis for bone tumours: A case series. *Int J Sci Res* 2020;9:144-7.
34. Sinha SK, Das A, Das A, Ghosh S. Limb salvage surgery with endoprosthesis reconstruction in management of locally advanced primary bone tumours: A functional outcome evaluation. *Int J Res Orthop* 2022;8:214-21.
35. Bilal M, Jilani S, Rafi I, Shakeel O, Jabeen W. Early outcomes of limb salvage surgery with mega-prosthesis: A single center experience. *J Acute Dis* 2021;10:208-15.
36. Natarajan MV, Sameer MM, Upadhyay U, Kumar MD. Custom mega prosthesis in metachronous osteosarcoma. *Ann Natl Acad Med Sci* 2020;53:73-8.
37. Fernandes LD, Villadsen A, Holm CE, Sørensen MS, Zebis MK, Andersen LL, et al. Work ability and physical activity after major bone sarcoma resection and reconstruction with tumour prosthesis of the lower extremities: A cross-sectional study. *Disabil Rehabil* 2023;45:2597-603.
38. Satish MS, Vijay S, Raja A, Veeraiah S. Quality of life and functional outcome of patients treated with revision limb salvage surgery and amputation: A cross-sectional study. *J Bone Soft Tissue Tumors* 2019;5:11-4.
39. Pu F, Yu Y, Shao Z, Wu W, Feng J, Chen F, et al. Clinical efficacy of customized modular prosthesis in the treatment of femoral shaft metastases. *Front Oncol* 2023;13:1115898.
40. Lin T, Jin Q, Mo X, Zhao Z, Xie X, Zou C, et al. Experience with periprosthetic infection after limb salvage surgery for patients with osteosarcoma. *J Orthop Surg Res* 2021;16:93.
41. Pesenti S, Peltier E, Pomero V, Authier G, Roscigni L, Viehweger E, et al. Knee function after limb salvage surgery for malignant bone tumor: Comparison of megaprosthesis and distal femur allograft with epiphysis sparing. *Int Orthop* 2018;42:427-36.
42. Ng YH, Chai YC, Mazli N, Jaafar NF, Ibrahim S. Outcome of endoprosthesis used in limb salvage surgery in a Malaysian orthopaedic oncology centre. *Malays Orthop J* 2024;18:60-5.



43. Shah MR, Shah MM, Agrawal AK, Shah MD, Desai SM. Functional outcome of limb salvage surgery by mega-prosthesis

for malignant bone tumors-mid and long-term follow-up. Int J Curr Res Rev 2020;12:189-94.

**Conflict of Interest:** Nil

**Source of Support:** Nil

**Consent:** The authors confirm that informed consent was obtained from the patient for publication of this article

#### How to Cite this Article

Sharma A, Guliani R, Bindal S. Functional Outcomes and Complications of Megaprosthesis Reconstruction in Limb-Salvage Surgery for Musculoskeletal Tumors: A Scoping Review. Journal of Orthopaedic Case Reports 2026 May;16(05): 536-544.

